Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry

INTRODUCTION: ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety,...

Descripción completa

Detalles Bibliográficos
Autores principales: Menter, Alan, Thaçi, Diamant, Wu, Jashin J., Abramovits, William, Kerdel, Francisco, Arikan, Dilek, Guo, Dianlin, Ganguli, Arijit, Bereswill, Mareike, Camez, Anne, Valdecantos, Wendell C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574748/
https://www.ncbi.nlm.nih.gov/pubmed/28815476
http://dx.doi.org/10.1007/s13555-017-0198-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574748/
https://www.ncbi.nlm.nih.gov/pubmed/28815476
http://dx.doi.org/10.1007/s13555-017-0198-x

Ejemplares similares